Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Core Insights - Genprex, Inc. announced positive preclinical data for its Reqorsa® Gene Therapy, indicating its potential effectiveness in treating ALK-EML4 positive non-small cell lung cancer (NSCLC) [1][2] - The therapy demonstrated a 79% tumor shrinkage rate, outperforming alectinib, which showed a 60% reduction [7] Company Overview - Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its Oncoprex® Delivery System to administer gene therapies [10] - The lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently being evaluated in clinical trials for NSCLC and small cell lung cancer (SCLC) [10] Research Findings - Preclinical studies showed that Reqorsa can induce apoptosis in ALK+ NSCLC cell lines and patient-derived organoids, leading to significant tumor reduction [6][8] - The combination of Reqorsa and alectinib resulted in a 23% improved outcome compared to alectinib alone, suggesting its potential as a companion drug for advanced disease [7] Upcoming Presentations - Positive preclinical data will be presented at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting the efficacy of Reqorsa in NSCLC [1][3]